JPS646170B2 - - Google Patents

Info

Publication number: JPS646170B2
Authority: JP; Japan
Prior art keywords: amoxicillin; solution; sodium; drying; sodium hydroxide
Prior art date: 1978-10-03
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

JP54127848A

Other languages

English (en)

Japanese (ja)

Other versions

JPS5562009A (en

Inventor

De Yonje Haio

Uiremu Furenendaaru Yan

Yan Shiiburandosu Herurito

Baheruman Deetoman Annita

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Gist Brocades NV

Original Assignee

Gist Brocades NV

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1978-10-03

Filing date

1979-10-03

Publication date

1989-02-02

1979-10-03 Application filed by Gist Brocades NV filed Critical Gist Brocades NV

1980-05-10 Publication of JPS5562009A publication Critical patent/JPS5562009A/ja

1989-02-02 Publication of JPS646170B2 publication Critical patent/JPS646170B2/ja

Status Granted legal-status Critical Current

Links

HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 63
LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims description 44
229960002793 amoxicillin sodium Drugs 0.000 claims description 36
ILVPFTMKCHREDJ-UHFFFAOYSA-N methyl 5-amino-2-fluorobenzoate Chemical compound COC(=O)C1=CC(N)=CC=C1F ILVPFTMKCHREDJ-UHFFFAOYSA-N 0.000 claims description 36
238000000034 method Methods 0.000 claims description 32
229960003022 amoxicillin Drugs 0.000 claims description 25
LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims description 25
238000002360 preparation method Methods 0.000 claims description 23
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 18
238000007710 freezing Methods 0.000 claims description 15
230000008014 freezing Effects 0.000 claims description 15
229960004920 amoxicillin trihydrate Drugs 0.000 claims description 14
238000004519 manufacturing process Methods 0.000 claims description 11
239000007900 aqueous suspension Substances 0.000 claims description 4
229940102223 injectable solution Drugs 0.000 claims description 4
238000002156 mixing Methods 0.000 claims description 2
230000003472 neutralizing effect Effects 0.000 claims 1
239000000243 solution Substances 0.000 description 69
238000001035 drying Methods 0.000 description 53
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 33
239000007864 aqueous solution Substances 0.000 description 21
238000004108 freeze drying Methods 0.000 description 18
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 17
239000000047 product Substances 0.000 description 16
238000001816 cooling Methods 0.000 description 10
239000000203 mixture Substances 0.000 description 9
229910052753 mercury Inorganic materials 0.000 description 8
QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 8
229910052757 nitrogen Inorganic materials 0.000 description 8
238000004448 titration Methods 0.000 description 8
238000000354 decomposition reaction Methods 0.000 description 7
238000010438 heat treatment Methods 0.000 description 7
238000002347 injection Methods 0.000 description 7
239000007924 injection Substances 0.000 description 7
239000007788 liquid Substances 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
238000004458 analytical method Methods 0.000 description 6
238000003756 stirring Methods 0.000 description 6
230000000052 comparative effect Effects 0.000 description 5
239000007857 degradation product Substances 0.000 description 5
239000011888 foil Substances 0.000 description 5
239000002904 solvent Substances 0.000 description 5
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
229960000723 ampicillin Drugs 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
239000002270 dispersing agent Substances 0.000 description 4
238000009472 formulation Methods 0.000 description 4
229920003023 plastic Polymers 0.000 description 4
239000004033 plastic Substances 0.000 description 4
229910052782 aluminium Inorganic materials 0.000 description 3
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
KLOHDWPABZXLGI-YWUHCJSESA-M ampicillin sodium Chemical compound [Na+].C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C([O-])=O)(C)C)=CC=CC=C1 KLOHDWPABZXLGI-YWUHCJSESA-M 0.000 description 3
229960001931 ampicillin sodium Drugs 0.000 description 3
239000002585 base Substances 0.000 description 3
239000002775 capsule Substances 0.000 description 3
238000011049 filling Methods 0.000 description 3
239000000843 powder Substances 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
238000001228 spectrum Methods 0.000 description 3
229910001220 stainless steel Inorganic materials 0.000 description 3
239000010935 stainless steel Substances 0.000 description 3
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
229930182555 Penicillin Natural products 0.000 description 2
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
-1 alkali metal salts Chemical class 0.000 description 2
229960000603 cefalotin Drugs 0.000 description 2
VUFGUVLLDPOSBC-XRZFDKQNSA-M cephalothin sodium Chemical compound [Na+].N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C([O-])=O)C(=O)CC1=CC=CS1 VUFGUVLLDPOSBC-XRZFDKQNSA-M 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
238000009792 diffusion process Methods 0.000 description 2
230000000694 effects Effects 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000013020 final formulation Substances 0.000 description 2
239000010419 fine particle Substances 0.000 description 2
235000010445 lecithin Nutrition 0.000 description 2
239000000787 lecithin Substances 0.000 description 2
229940067606 lecithin Drugs 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
230000000813 microbial effect Effects 0.000 description 2
238000006386 neutralization reaction Methods 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
230000000704 physical effect Effects 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
230000001954 sterilising effect Effects 0.000 description 2
239000000126 substance Substances 0.000 description 2
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
229930186147 Cephalosporin Natural products 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical group OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
229940124587 cephalosporin Drugs 0.000 description 1
150000001780 cephalosporins Chemical class 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
229910001873 dinitrogen Inorganic materials 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
238000002329 infrared spectrum Methods 0.000 description 1
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
239000002245 particle Substances 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
150000002960 penicillins Chemical class 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
150000003138 primary alcohols Chemical class 0.000 description 1
238000010791 quenching Methods 0.000 description 1
230000000171 quenching effect Effects 0.000 description 1
239000002994 raw material Substances 0.000 description 1
238000007086 side reaction Methods 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
WUWHFEHKUQVYLF-UHFFFAOYSA-M sodium;2-aminoacetate Chemical compound [Na+].NCC([O-])=O WUWHFEHKUQVYLF-UHFFFAOYSA-M 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

JP12784879A 1978-10-03 1979-10-03 Manufacture of ammoxysilinsodium medicine Granted JPS5562009A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
NL7809986A NL7809986A (nl)	1978-10-03	1978-10-03	Werkwijze voor het bereiden van natrium amoxicilline geschikt voor injectiepreparaten, alsmede deze verbin- ding bevattende gedoseerde injectiepreparaten en de bereiding ervan.

Publications (2)

Publication Number	Publication Date
JPS5562009A JPS5562009A (en)	1980-05-10
JPS646170B2 true JPS646170B2 (fr)	1989-02-02

Family

ID=19831645

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP12784879A Granted JPS5562009A (en)	1978-10-03	1979-10-03	Manufacture of ammoxysilinsodium medicine

Country Status (3)

Country	Link
JP (1)	JPS5562009A (fr)
BE (1)	BE879174A (fr)
NL (1)	NL7809986A (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH07178253A (ja) *	1993-12-22	1995-07-18	Nkk Corp	水上を自走可能な遊戯用乗り物

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS60102710A (ja) *	1983-11-09	1985-06-06	Hitachi Ltd	油入電器の異常監視装置
WO2006072577A1 (fr) *	2005-01-07	2006-07-13	Sandoz Ag	Procede de preparation de granules comprenant de l’amoxicilline

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5283915A (en) *	1976-01-01	1977-07-13	Beecham Group Ltd	Amoxycillin solution

1978
- 1978-10-03 NL NL7809986A patent/NL7809986A/nl not_active Application Discontinuation
1979
- 1979-10-03 JP JP12784879A patent/JPS5562009A/ja active Granted
- 1979-10-03 BE BE0/197458A patent/BE879174A/fr not_active IP Right Cessation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH07178253A (ja) *	1993-12-22	1995-07-18	Nkk Corp	水上を自走可能な遊戯用乗り物

Also Published As

Publication number	Publication date
JPS5562009A (en)	1980-05-10
BE879174A (fr)	1980-04-03
NL7809986A (nl)	1980-04-09

Publication	Publication Date	Title
JP2527776B2 (ja)	1996-08-28	凍結乾燥投与形の製造方法
US5283067A (en)	1994-02-01	Parenteral suspensions
NZ205083A (en)	1986-03-14	1-acetoxyethyl ester of(6r,7r)-3-carbamoyloxymethyl-7((z)-2-(fur-2-yl)-2-methoxyiminoacetamido)ceph-3-em-carboxylic acid and pharmaceutical compositions
JP3267611B2 (ja)	2002-03-18	リポソーム−ポリエンプレリポソーム粉末とその製造方法
EA024814B1 (ru)	2016-10-31	Медицинское устройство, содержащее композицию сухого остатка, содержащую арипипразол в качестве активного ингредиента, и композиция сухого остатка, содержащая арипипразол в качестве активного ингредиента
JP2883890B2 (ja)	1999-04-19	抗生物質溶液およびその凍結乾燥法
EP0724581A1 (fr)	1996-08-07	Mofetil de mycophenolate anhydre cristallin et sa formulation intraveineuse
CN113197870B (zh)	2022-07-01	一种注射用丝裂霉素冻干制剂及其制备方法
JPS6019758B2 (ja)	1985-05-17	非径口投与用セフアゾリンナトリウムの製法
US4607029A (en)	1986-08-19	Novel sodium amoxicillin preparations
JPS646170B2 (fr)	1989-02-02
TW565565B (en)	2003-12-11	Crystalline amrubicin hydrochloride
RU2134112C1 (ru)	1999-08-10	Стабильная лиофилизированная композиция тиотепа и способ ее получения
JPH07504892A (ja)	1995-06-01	グリセロホスホコリンの製造のための結晶化方法
AU612343B2 (en)	1991-07-11	A dry formulation for the preparation of a suspension of diclofenac in salt form; and a stable suspension produced therefrom
US4002748A (en)	1977-01-11	Method of preparing sterile essentially amorphous cefazolin for reconstitution for parenteral administration
CN100528141C (zh)	2009-08-19	注射用盐酸川芎嗪冻干剂及其制备方法
US20230225976A1 (en)	2023-07-20	Lyophilized formulation containing cephalosporin having catechol group and the manufacturing method
JP2988631B2 (ja)	1999-12-13	ホスホマイシンナトリウムの凍結乾燥製剤およびその製造法
RU2382649C2 (ru)	2010-02-27	Пероральная лекарственная форма с немедленным высвобождением малорастворимого активного вещества
JP4407813B2 (ja)	2010-02-03	パニペネム含有製剤
US4316886A (en)	1982-02-23	Process for the preparation of solid sodium amoxycillin
NL7900021A (nl)	1980-07-07	Werkwijze voor het bereiden van natriumamoxicilline geschikt voor injectiepreparaten, alsmede deze verbin- ding bevattende gedoseerde injectiepreparaten en de be- reiding ervan.
US6048552A (en)	2000-04-11	DASC compositions, process for preparing same and suspensions containing same
CN101254175A (zh)	2008-09-03	一种富马酸尼唑苯酮冻干粉及其制备方法

JPS646170B2 - - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (1)

Publications (2)

Family

ID=19831645

Family Applications (1)

Country Status (3)

Cited By (1)

Families Citing this family (2)

Family Cites Families (1)

Cited By (1)

Also Published As

Similar Documents